The global clinical nutrition for cancer care market size was estimated at around USD 5.66 billion in 2023 and it is projected to hit around USD 9.29 billion by 2033, growing at a CAGR of 5.08% from 2024 to 2033.
The clinical nutrition for cancer care market is witnessing significant growth as healthcare providers increasingly recognize the crucial role of nutrition in supporting cancer treatment outcomes.
The growth of the clinical nutrition for cancer care market is driven by the rising prevalence of cancer worldwide is driving demand for specialized nutritional interventions to support patients throughout their treatment journey. Additionally, advancements in medical nutrition therapy and the development of innovative nutritional products tailored to the unique needs of cancer patients are contributing to market expansion. Moreover, increasing awareness among healthcare professionals about the critical role of nutrition in cancer care is leading to greater adoption of evidence-based nutrition interventions, further driving market growth. Furthermore, the growing trend towards personalized medicine and multidisciplinary approaches to cancer treatment is creating opportunities for the development of customized nutrition plans that can optimize treatment outcomes and improve patient quality of life.
In 2023, oral clinical nutrition emerged as the dominant force in the market, commanding over 45% of the market share. These orally administered nutrition products specifically target cancer-related malnutrition, which stems from metabolic dysregulation and anorexia induced by both the tumor and its treatment. Their pivotal role lies in improving the quality of life for cancer patients by thwarting malnutrition, mitigating complications, and enhancing clinical outcomes. Additionally, these products are formulated to address common taste and smell alterations experienced by patients undergoing systemic antitumor therapy. Furthermore, their ease of consumption makes them highly suitable for patients who possess the ability to eat but face malnutrition or are at risk of it.
Looking ahead, the parenteral nutrition segment is poised for rapid growth during the forecast period. Parenteral nutrition assumes critical significance in cancer care due to the high prevalence of malnutrition among patients. Malnutrition not only leads to muscle depletion but also diminishes treatment response and overall quality of life. Hence, parenteral nutrition administers vital nutrients directly into the bloodstream, bypassing the digestive system. This method effectively slows down protein breakdown and reverses protein loss in organs, thereby potentially amplifying treatment outcomes.
In 2023, adults dominated the segment, commanding over 81% of the market revenue share, and are projected to experience the most rapid growth throughout the forecast period. This trend is primarily driven by the prevalent occurrence of malnutrition among adult cancer patients. Clinical nutrition interventions have the potential to mitigate protein degradation and combat organ protein loss, ultimately leading to potential improvements in treatment outcomes. Furthermore, the implementation of clinical nutrition strategies is carefully tailored to each patient, taking into account their unique health circumstances and nutritional requirements.
According to the CDC, approximately 58% of cancer cases are diagnosed in adults aged 65 years or older. To address their specific nutritional needs, there has been a notable surge in the introduction of new oncology nutrition products. These products are specifically formulated to assist patients in managing diseases and coping with the side effects of treatment. Moreover, there is a growing recognition of the critical role of nutrition in cancer care, with increasing emphasis placed on its impact on patient health and well-being. This concerted effort includes the collaborative design of cancer nutrition care pathways, which is expected to further drive market growth.
In 2023, institutional sales emerged as the frontrunner in market revenue, commanding over 41% share. These institutions encompass government organizations, hospitals, and research institutes. With the escalating prevalence of cancer, there's a growing imperative for heightened nutritional support, precipitating a surge in clinical nutrition sales within hospital settings. Recent healthcare reforms have exerted pressure on hospitals to deliver cost-efficient, high-quality care, thereby fueling the demand for clinical nutrition products. Essentially, the robust demand for clinical nutrition for cancer care, combined with the expanding influence of hospitals and the intricacies of healthcare systems, elucidates why hospitals and institutional sales dominate clinical nutrition sales.
Meanwhile, the online sales segment is poised for the fastest growth over the forecast period. Advancements in telemedicine have facilitated the global dissemination of clinical nutrition products, enabling manufacturers to broaden their market outreach and cater to underserved communities. Consequently, online sales have experienced a notable upsurge owing to the mounting customer demand for medical foods tailored to address nutrition-based deficiencies in cancer patients.
North America asserted its dominance in the market by capturing nearly 35% of the revenue share in 2023, and is poised to exhibit the fastest Compound Annual Growth Rate (CAGR) over the forecast period. Diseases such as esophageal cancer, gastric cancer, head & neck cancer, and laryngeal cancer often impede oral food intake in patients. The escalating prevalence of these conditions is anticipated to propel the demand for enteral and parenteral nutrition solutions in the region.
In 2023, Europe emerged as the second-largest regional market for clinical nutrition for cancer care. The region has proposed evidence-based recommendations concerning the organization of food catering, prescriptions, and indications of diets, as well as the monitoring of food intake at hospitals, rehabilitation centers, and nursing homes. The burgeoning healthcare expenditure in Europe is expected to drive technological advancements in the healthcare sector, thereby boosting the parenteral nutrition market in the region. Additionally, favorable reimbursement policies, increasing government investments in long-term healthcare, and enhancements in healthcare research infrastructure are anticipated to augment the utilization rates of parenteral nutrition over the next seven years.
By Product
By Stage
By Sales Channel
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Product Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Clinical Nutrition for Cancer Care Market
5.1. COVID-19 Landscape: Clinical Nutrition for Cancer Care Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Clinical Nutrition for Cancer Care Market, By Product
8.1. Clinical Nutrition for Cancer Care Market, by Product, 2024-2033
8.1.1 Oral Nutrition
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Parenteral Nutrition
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Enteral Feeding Formulas
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Clinical Nutrition for Cancer Care Market, By Stage
9.1. Clinical Nutrition for Cancer Care Market, by Stage, 2024-2033
9.1.1. Stage
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Pediatric
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Clinical Nutrition for Cancer Care Market, By Sales Channel
10.1. Clinical Nutrition for Cancer Care Market, by Sales Channel, 2024-2033
10.1.1. Online
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Institutional Sales
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Clinical Nutrition for Cancer Care Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Forecast, by Stage (2021-2033)
11.1.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Forecast, by Stage (2021-2033)
11.2.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Stage (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Stage (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Forecast, by Stage (2021-2033)
11.3.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Stage (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Stage (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Stage (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Stage (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Stage (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Stage (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Sales Channel (2021-2033)
Chapter 12. Company Profiles
12.1. Abbott Nutrition.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bayer AG.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Nestle Health Science S.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline plc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Baxter International Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Otsuka Holdings Co., Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mead Johnson & Company, LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Danone Nutricia.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Victus, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms